LAG-3，通过与多种配体的相互作用，通过抑制T细胞增殖和活化来调节T细胞功能。已证明它在多种癌症的肿瘤浸润淋巴细胞（TIL）上过表达，并伴有不良预后。目的探讨LAG-3在小儿霍奇金淋巴瘤(HL)中的表达规律及临床意义。使用免疫组织化学分析来自儿童肿瘤学组临床试验AHOD0031的患者肿瘤样品与匹配的患者结果数据的LAG-3和PD-L1的表达。73/115例患者(63%)显示LAG-3染色阳性。没有人口统计学或生存结果数据与LAG-3表达显著相关。有趣的是,表达密度最低的患者发现EFS最差，表达密度最高的那些表现出最好的EFS。LAG-3的存在与PD-L1表达之间存在统计学上显著的正相关关系。该项目在将LAG-3表征为小儿HL的免疫检查点靶标方面具有创新性。
LAG-3, through interaction with a variety of ligands, regulates T cell function via inhibition of T cell proliferation and activation. It has been demonstrated to be overexpressed on tumor infiltrating lymphocytes (TILs) of a variety of cancers with associated poor outcomes. The purpose of this study is to characterize the expression pattern and clinical significance of LAG-3 in pediatric Hodgkin lymphoma (HL). Patient tumor samples from Children\'s Oncology Group clinical trial AHOD0031 with matched patient outcome data were analyzed for the expression of LAG-3 and PD-L1 using immunohistochemistry. 73/115 patients (63%) demonstrated positive LAG-3 staining. No demographic or survival outcome data were significantly associated with LAG-3 expression. Interestingly, patients with the lowest density of expression were found to have the worst EFS, and those with highest density of expression demonstrated the best EFS. There was a positive statistically significant relationship between presence of LAG-3 and PD-L1 expression. This project is innovative in its characterization of LAG-3 as an immune checkpoint target in pediatric HL.
PDF(Sci-hub)